▮ Entertainment

Top Stories
Slide Shows
Game of Thrones
▮ Music news
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre

▮ Content Licensing

▮ More

Wall Street Events

Plus

Neg

Email

Enterprise Products Partners Investor & Analyst Day Webcast At 9:00 AM ET

By RTTNews Staff Writer ✉ | Published: 3/7/2018 8:01 AM ET

Enterprise Products Partners LP (EPD) will host a meeting with securities analysts and investors in Houston at 9:00 AM ET on March 7, 2018.

To access live webcast www.enterpriseproducts.com

For comments and feedback contact: editorial@rttnews.com

Coronavirus Vaccines In Human Trials COVID19 Antibodies Spike Protein US Operation Warp Speed

Tracking Coronavirus Vaccines In Human Trials

Biotech Stocks Facing FDA Decision In July 2020 Virtual Meetings Pandemic Rare Diseases colonoscopy and bronchoscopy

Biotech Stocks Facing FDA Decision In July 2020

New Drugs Approved In May

New Drugs Approved In May

Latest Updates on COVID-19

Novavax Gets $1.6 Bln Federal Grant For Covid-19 Vaccine

EU Gives Conditional Market Authorization For Gilead's Remdesivir Treat COVID-19

Sanofi, Regeneron Stop Kevzara COVID-19 Trial In U.S. After Failing To Meet Key Goals

U.S. Secures Most Of Remdesivir Supply Till September

Pfizer And BioNTech' Potential Covid-19 Vaccine Shows Positive Data In Human Trial

Tracking Coronavirus Vaccines In Human Trials

Read More

COVID-19: Drugs in Development

RELATED NEWS

Enterprise Products Cuts Total 2020 Growth Capital Investments - Quick Facts

Enterprise Products Partners LP Earnings Rise In Q1

Follow RTT

Editor's Pick
Most Read
Most Emailed

Walmart Offers Easy, Contact-free Shopping For Back-to-school Essentials

Bed Bath & Beyond To Close Around 200 Stores

United Airlines May Furlough 36,000 Employees

Walmart To Launch New Subscription Program Walmart+ In July: Report

Walgreens And VillageMD To Open 500-700 Physician-led Primary Care Clinics

VillageMD To Open Clinics In 500-700 Walgreens Stores

Mylan Recalls One Lot Of Daptomycin For Injection

Novavax Gets $1.6 Bln Federal Grant For Covid-19 Vaccine

Warren Buffett Contributes $2.9 Bln Worth "B" Shares Of Berkshire To Five Philanthropies

Lupin Pharma Recalls Diabetes Drug Metformin

One Of The Vaccine Candidates Will Enter Phase III Trial By July End: Dr.Fauci

Granules Pharma Recalls Diabetes Drug Metformin HCI Extended-Release Tablets

Pre-market Movers In Healthcare Sector: NVAX, ENDP, VXRT, EOLS, CLLS…

Granules Pharma Recalls Diabetes Drug Metformin HCI Extended-Release Tablets

BELLUS Health: BLU-5937 RELIEF Trial Did Not Achieve Statistical Significance For Primary Goal

Stock Alert: Esports Entertainment Up 12% On Argyll Entertainment Acquisition

Croda To Acquire Avanti Polar Lipids - Quick Facts

CRVS, HEPA Jump On COVID-19 Drug Bandwagon, LVGO In Good Health, NVAX Joins $100 Stock Price Club

DXC Technology Says Its Subsidiary Xchanging Experienced Ransomware Attack

Stock Alert: Biogen Up 5%; Submits Application To FDA For Aducanumab

Ascentage, Merck To Evaluate APG-115 In Combination With KEYTRUDA In Advanced Solid Tumors

Commerzbank CEO Martin Zielke Offers To Resign; Chairman Quits

Pre-Market Movers In Healthcare Sector - OBSV, MGTA, ELGX...

Merck: New Analyses Show Additional Efficacy Data For Islatravir, Doravirine Combination

LabCorp Launches Home Collection Kit To Test COVID-19 - Quick Facts

Curis Doses First Patient In Phase 1 Trial Evaluating CA-4948 - Quick Facts

Bombardier Transportation Enters 4-yr Maintenance Contract With Vy Tåg

Eni Affirms Decarbonization Strategy; Revises Long-term Price Projections

Deutsche Bank, Google Cloud To Enter Strategic Partnership - Quick Facts

Derwent London Says Received 75% Of June Quarter's Office Rents

Assura Plc Issues Trading Update - Quick Facts

Heidelbergcement To Take EUR 3.4 Bln Asset Impairment In Q2

Stock Alert: Mesoblast Shares Up 10%

ANI Pharma Acquires Fluconazole Tablets For $3.0 Mln

Uber To Acquire Postmates In All-stock Deal Valued At Approx. $2.65 Bln

Emergent Signs 5-yr Manufacturing Deal For Johnson & Johnson's COVID-19 Vaccine Candidate